Risk models predicting survival after reduced‐intensity transplantation for myelofibrosis
暂无分享,去创建一个
N. Kröger | A. Zander | E. Holler | G. Kobbe | M. Bornhäuser | G. Büsche | W. Bethge | H. Kvasnicka | U. Bacher | F. Ayuk | T. Zabelina | H. Alchalby | R. Schwerdtfeger | Dinah-Rohina Yunus
[1] A. Tefferi,et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Bernard,et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC) , 2011, British journal of haematology.
[3] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Y. Hildebrandt,et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. , 2010, Blood.
[5] M. Cazzola,et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. , 2010, Blood.
[6] N. Kröger,et al. Outcome of transplantation for myelofibrosis. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] G. Barosi,et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type , 2010, Bone Marrow Transplantation.
[8] A. Duhamel,et al. Comparison of prognostic scoring systems in primary myelofibrosis. , 2010, Blood.
[9] A. Tefferi,et al. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. , 2010, Blood.
[10] H. Einsele,et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2009, Blood.
[11] H. Kantarjian,et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Brand,et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation , 2009, Cancer.
[13] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[14] D. Rondelli. Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2008, Haematologica.
[15] G. Barosi,et al. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders , 2008, Leukemia.
[16] F. M. Stewart,et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] J. Panse,et al. Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis , 2005, British journal of haematology.
[18] J. D. van der Walt,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.
[19] H. Deeg,et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. , 2003, Blood.
[20] H. Deeg,et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. , 1999, Blood.
[21] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.
[22] E. Montserrat,et al. Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups , 1998, British journal of haematology.
[23] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Lancet.
[24] P. Morel,et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.